Ebola and Sudan Virus Vaccines Show Cross-Protection Against Bundibugyo Virus in Preclinical Study
A preclinical study found that vaccines developed against Ebola virus (EBOV) and Sudan virus (SUDV) provided cross-protective immunity against Bundibugyo virus (BDBV) in mouse models. The protection appeared to work through non-neutralizing immune mechanisms rather than antibody neutralization alone. The findings suggest existing ebolavirus vaccines may offer some protection against BDBV, which is currently causing a public health emergency in Central-East Africa.
Researchers developed a surrogate challenge model to test whether existing vaccines against related ebolavirus species could protect against Bundibugyo virus. A yellow fever 17D-vectored BDBV vaccine (YF-BDB) provided complete protection against BDBV challenge in immunocompromised mice. Notably, vaccines targeting EBOV and SUDV also protected mice from BDBV challenge, though the protection was asymmetrical—EBOV and BDBV vaccines only partially protected against SUDV. Serological analysis showed cross-reactive antibodies across vaccine groups, but neutralization capacity was limited, suggesting non-neutralizing immune mechanisms play a major role in protection. The study indicates that SUDV-based antigens may provide broader protection than EBOV or BDBV candidates, and adds preliminary evidence that EBOV vaccines might offer some degree of protection against BDBV during the current outbreak.
What's missing
The study was conducted in mouse models (Ifnar-/- mice), which may not fully translate to human immune responses. The mechanisms underlying non-neutralizing protection are not fully characterized. Clinical efficacy in humans remains to be determined.
What different sources said
- bioRxivCenter
Cross-protection against Bundibugyo by Ebola and Sudan vaccines
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.